Compare ProShares Ultra QQQ ETF (QLD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Zoetis Inc — how do they compare? ProShares Ultra QQQ ETF trades at $98.31 (market cap $15.38B), while Zoetis Inc trades at $74.57 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 36 Days and Zoetis Inc for 70 Days on average.
| QLD | ZTS | |
|---|---|---|
Market Cap | $15.38B | $30.20B |
Volume | 4,844,085 | 6,175,327 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $147.53 |
52-Week Low | $57.16 | $69.09 |
Typical Hold Time | 36 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD, the ProShares Ultra QQQ ETF, trades at $98.43, down 1.8% on the day, with a bullish technical signal driven by moving averages. The ETF aims to deliver twice the daily return of the Nasdaq-100 Index. Recent news highlights its resilience compared to higher-leverage counterparts during market downturns, with institutional buying noted in Q2 2026.
The outlook hinges on Nasdaq-100 performance and Federal Reserve policy, with support at $96 and resistance at $100. Risks include market volatility and leverage decay. Analyst sentiment is mixed, advising caution until technical confirmation above key moving averages.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
